An interventional study of Multi-strain probiotics in Constipation, Probiotic and Probiotic Intervention, sponsored by Dr Anthony Hobson. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Dr Anthony Hobson · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Constipation with a site in United Kingdom — 4 open to participants now, 5 under way, none of them phase 3. Constipation · United Kingdom.
Among the 61 studies in Constipation with a site in United Kingdom, this one is the 42nd largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2025, is one of 23 with no phase, and was the 58th registered.
1,048 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →4 of the 61 studies in Constipation with a site in United Kingdom are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United Kingdom, United States, Belgium and 5 more countries
Ages 18–75
University of Cambridge · Sites in United Kingdom
Ages 55+ · Healthy volunteers
usMIMA S.L. · Sites in United Kingdom
Ages 18+
University of Nottingham · Sites in United Kingdom
Ages 6+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 15 · Phase 4 6
First in 1998; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 75 across 886 interventional studies indexed under Constipation.
Median enrollment 93 across the 54 interventional studies, 170 across the 7 observational. Of the 50 that completed or were terminated, 16 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 61 have an industry lead sponsor. The 10 most frequent:
Dr Anthony Hobson is the lead sponsor of 6 studies on the registry; none are open to participants now.
Dr Anthony Hobson has 1 study filed under Constipation — fewer than ten, so there is no comparison to draw.
2 of the studies in Constipation with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07786116University of CambridgeThe Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions | 2027-06 |
| NCT07545772Eli Lilly and CompanyA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 61 studies in Constipation with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Constipation is a prevalent gastrointestinal condition. Beyond simple lifestyle measures (e.g. increasing fibre intake, hydration, levels of exercise), medical therapies are available for management. However, a sizeable number of sufferers are dissatisfied with drug treatments (either over-the-counter or prescribed), meaning there is an unmet need for alternative therapeutic strategies.
Pre, pro- and synbiotics have emerged as one alternative treatment, and a growing body of evidence now supports their use in a proportion of individuals with mild constipation. However, it is currently not possible to predict which individuals may benefit. A better understanding of an individuals' symptoms and underlying pathophysiology may allow for more targeted treatment.
The multistrain live bacterial food product (probiotic) being tested contains billions of live and active bacteria that has been shown to improve symptoms in the irritable bowel syndrome (IBS: which is 'constipation-predominant' in many). Notably, improvements ('completely resolved' or 'some positive difference') in bowel habit satisfaction, abdominal pain, bloating and urgency, as well as on quality of life have been shown after 4 or more weeks of this probiotc.
This study aims to have 20 participants with self-reported constipation to assess improvements in constipation symptoms, quality of life and measures of gut function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If participant is willing to adhere to one of the following methods of :
i) Hormonal contraception e.g. the 'pill' or an implant ii) Intrauterine device (IUD) iii) Intrauterine hormone-releasing system (IUS) vi) Sexual abstinence (if it is in line with participants' preferred and usual lifestyle).
or has had a: v) Hysterectomy or has a: vi) Vasectomised partner
Exclusion Criteria:
Known organic or structural GI disease including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
70ml of a multi-strain liquid probiotic taken daily for 28-35 days
Dietary Supplement: Multi-strain probiotics
28-35 days of 70 ml Symprove once daily, to be taken on an empty stomach upon waking. 10 minutes should be taken between ingestion of Symprove before eating and drinking.
Patient Assessment of Constipation-Symptoms (PAC-SYM)
Number of participants with clinically meaningful change in PAC-SYM score (reduction of \>0.6 or \>0.75 points). The PAC-SYM questionnaire is a 12 item validated patient-reported measure of severity of constipation symptoms during the past two weeks.
Time frame: Pre-post comparison (28 days)
Patient Assessment of Constipation - Quality of Life (PAC-QoL)
Number of participants with clinically meaningful change in PAC-QoL (reduction of \>0.5 or \>1.0 point). A validated questionnaire consisting of 28 items to measure the impact of constipation on a patient's quality of life.
Time frame: Pre-Post comparison (28 days)
Participant Compliance
Number of participants completing \>75% of breath gas measurements and bowel diary submissions with OMED device. The OMED Health Breath Analyzer is used for breath gas readings at 4 intervals during the day. The bowel diary recorded daily on paper throughout the study capturing movements, symptoms and any medication
Time frame: Pre-Post comparison (28 days)
Whole Gut Transit Time (ATMO)
Change in whole gut transit time measured by ATMO capsule ATMO capsule is an ingestible electronic medical device measuring gastrointestinal (GI) transit time and environmental conditions as it moves through the digestive tract.
Time frame: Pre-Post comparison (28 days)
Whole Gut Transit Time (Blue-dye)
Change in whole gut transit time measured by Blue dye transit study baseline period to treatment period. Participants are required to consume a Zoe blue cookie the following morning after both visits 2 and 3. Participants then report when the blue food colour is visible in their stool, checking every time they pass a bowel movement.
Time frame: Pre-Post comparison (28 days)
Small Bowel Transit Time (ATMO)
Change in small bowel transit time measured by ATMO capsule ATMO capsule is an ingestible electronic medical device measuring gastrointestinal (GI) transit time and environmental conditions as it moves through the digestive tract.
Time frame: Pre-Post comparison (28 days)
Large Bowel Transit Time (ATMO)
Change in large bowel transit time measured by ATMO capsule ATMO capsule is an ingestible electronic medical device measuring gastrointestinal (GI) transit time and environmental conditions as it moves through the digestive tract.
Time frame: Pre-Post comparison (28 days)
Gastrointestinal Symptom Rating Scale (GSRS)
Mean change in GSRS score A validated questionnaire consisting of 15items to assess range of GI symptoms. Scored using a seven-graded Likert scale, where 1 represents the most positive option and 7 the most negative one.
Time frame: Pre-Post comparison (28 days)
Stool form comparison
Average stool type recorded in two week baseline compared to average stool type recorded final two weeks of treatment period. Measured using the bristol stool chart reported in bowel habit diary.
Time frame: Pre-Post comparison (days 1-14 compared to days 29-42)
Stool frequency comparison
Average stool frequency recorded in two week baseline compared to average stool type recorded final two weeks of treatment period reported in bowel habit diary.
Time frame: Pre-Post comparison (days 1-14 compared to days 29-42)
Hydrogen and methane production
Assessment of longitudinal hydrogen and methane production during baseline and treatment periods. Recorded by OMED device 4x daily
Time frame: Pre-Post comparison (days 1-14 compared to days 15-42)
Global PAC-SYM
Comparison of global PAC-SYM score from baseline period to treatment period.
Time frame: Pre-Post comparison (28 days)
Inidividual PAC-SYM
Comparison of individual PAC-SYM symptom scores from baseline period to treatment period.
Time frame: Pre-Post comparison (28 days)
Straining
Self reported straining recorded in two week baseline compared to self reported straining during treatment period reported in bowel habit diary.
Time frame: Pre-Post comparison (days 1-14 compared to days 15-42)
Sense of complete evacuation
Self reported sense of complete evacuation recorded in two week baseline compared to self reported Sense of complete evacuation during treatment period reported in bowel habit diary.
Time frame: Pre-Post comparison (days 1-14 compared to days 15-42)
Time taken for evacuation
Self reported time taken for evacuation recorded in two week baseline compared to self reported time taken for evacuation during treatment period reported in bowel habit diary.
Time frame: Pre-Post comparison (days 1-14 compared to days 15-42)
Rescue Medication
Self reported use of rescue medication recorded in two week baseline compared to self reported use of rescue medication during treatment period reported in bowel habit diary.
Time frame: Pre-Post comparison (days 1-14 compared to days 15-42)
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Jul 2026, 9 months.
Of 245 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 9 months is below that.
Counting every sponsor, half of 316 studies reached it within 14 months; a quarter within 6 and three quarters within 30.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Apr 2026 → Jul 2026 and completion Apr 2026 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr Anthony Hobson